FUSION Clinical Trials has been engaged in clinical trials since 1989. Studies were initially conducted at the EMO ambulatory care centers in New Jersey. As a natural outgrowth of this activity, emergency department research and expansion to our California sites followed. Under our previous name, MedAmerica Clinical Research, we were the sole support organization for the 700 MedAmerica physicians across the country. As a result of our early success, other investigators affiliated with our institutions sought to join our organization. Although we initially made our training and support available to these new investigators, this practice deviated from our founding premise that investigator-owned site organizations are the most viable. In an industry where value-added support, flawless cohesion and streamlined initiations are the most compelling arguments for an SMO's existence, we felt that formally incorporating all the investigators within a single organization was imperative. Thus, the new organization was the FUSION of our MedAmerica sites and external sites into a single organization.

From its inception, FUSION has been designed as a support organization for the physician practices. In stark contrast to corporate SMO's that hire physicians, we are owned, and work for our investigators. This breeds intense loyalty and every PI knows that their individual performance affects the reputation of FUSION. This model also eliminates the problem of physician turnover. Every administrator and manager at FUSION is a scientist or clinician. We require each individual to maintain their expertise by participating in a trials as a CRC or PI annually. We expect hands-on trial experience and an active role in training sites, investigators and coordinators.

We provide access to large populations of patients that cannot be recruiting by advertising. Those in pain or acutely ill can't wait. The majority of our sites operate 7-days a week, 24-hours a day. The vast number of patients going through our sites has lead to top tier enrollment in many trials.

We limit the number of studies that can be done at any facility to avoid interference with the clinical portion of the practice. We will not place two similar studies at a site and the primary investigator will accept or decline studies after considering the ability of the site to complete the study in a timely fashion. While we have immediate access to over 700 physicians at nearly 90 sites, we make every attempt to place studies in those facilities that have the most appropriate patient population and frequency of visits for the condition being studied.

Today, FUSION Clinical Trials coruscates as the premier investigative site network in the emergency, urgent care and acute illness arena.